EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective

Jie Chen iD, Junrui Di iD, Nadia Daizadeh iD, Ying Lu iD, Hongwei Wang iD, Yuan-Li Shen iD, Jennifer Kirk, Frank W Rockhold iD, Herbert Pang iD, Jing Zhao iD, Weili He iD, Andrew Potter iD und 1 weitere

Clinical and Translational Science · 2025-02 · 18 (2)

DOI: 10.1111/cts.70117 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 19.02.2025. Verfasst von Jie Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, ECR Global, Shanghai, China. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There has been a growing trend that activities relating to clinical trials take place at locations other than traditional trial sites (hence decentralized clinical trials or DCTs), some of which are at settings of real‐world clinical practice. Although there are numerous benefits of DCTs, this also brings some implications on a number of issues relating to the design, conduct, and analysis of DCTs. The Real‐World Evidence Scientific Working Group of the American Statistical Association Biopharmaceutical Section has been reviewing the field of DCTs and provides in this paper considerations for decentralized trials from a statistical perspective. This paper first discusses selected critical decentralized elements that may have statistical implications on the trial and then summarizes regulatory guidance, framework, and initiatives on DCTs. More discussions are presented by focusing on the design (including construction of estimand), implementation, statistical analysis plan (including missing data handling), and reporting of safety events. Some additional considerations (e.g., ethical considerations, technology infrastructure, study oversight, data security and privacy, and regulatory compliance) are also briefly discussed. This paper is intended to provide statistical considerations for decentralized trials of medical products to support regulatory decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicHumansResearch DesignData Interpretation, Statistical

Stichwörter der Autor:innen

digital healthcare technologyestimandremote data acquisitionstatistical analysis plan

Autor:innen und Institutionen

  • Data Science, ECR Global, Shanghai, China.
  • Global Product Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Advanced Quantitative Sciences, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Data and Statistical Sciences AbbVie, North Chicago, Illinois, USA.
  • Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Jie Chen, Junrui Di, Nadia Daizadeh, Ying Lu, Hongwei Wang, Yuan-Li Shen, Frank W Rockhold, Herbert Pang, Jing Zhao, Weili He, Andrew Potter, Hana Lee

Zitieren

APA

Chen, J., Di, J., Daizadeh, N., Lu, Y., Wang, H., Shen, Y. L., Kirk, J., Rockhold, F. W., Pang, H., Zhao, J., He, W., Potter, A., & Lee, H. (2025). Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective. Clinical and Translational Science, 18(2). https://doi.org/10.1111/cts.70117

Vancouver

Chen J, Di J, Daizadeh N, Lu Y, Wang H, Shen YL, et al. Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective. Clinical and Translational Science. 2025;18(2). doi:10.1111/cts.70117

BibTeX
@article{Chen2025,
  author = {Chen, Jie and Di, Junrui and Daizadeh, Nadia and Lu, Ying and Wang, Hongwei and Shen, Yuan-Li and Kirk, Jennifer and Rockhold, Frank W and Pang, Herbert and Zhao, Jing and He, Weili and Potter, Andrew and Lee, Hana},
  title = {Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {2},
  doi = {10.1111/cts.70117}
}
Kostenlos starten →